<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04711915</url>
  </required_header>
  <id_info>
    <org_study_id>2000027720</org_study_id>
    <nct_id>NCT04711915</nct_id>
  </id_info>
  <brief_title>Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans</brief_title>
  <official_title>Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this fixed order, open-label, dose-escalation study is to investigate the safety&#xD;
      and efficacy of specific doses of dimethyltryptamine (DMT) in humans.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The results of this study will inform the doses to be used in a larger, double-blind,&#xD;
      randomized, placebo-controlled, crossover study. Since the goal of the open label study is to&#xD;
      inform the double-blind, randomized, placebo-controlled study, the investigators are citing&#xD;
      the hypothesis of the latter solely for providing context. The investigators hypothesize that&#xD;
      the administration of DMT will result in neuroplastic changes in healthy and depressed&#xD;
      subjects. These changes in neuroplasticity will be indexed using electroencephalographic&#xD;
      (EEG) measures and tasks. These neuronal changes may in parallel cause changes in mood&#xD;
      measured both in healthy and depressed subjects, which will be captured using appropriate&#xD;
      psychometric measures of mood.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 17, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Healthy individuals and patients with major depressive disorder will participate in this study. Subjects will receive 0.1 mg/kg and 0.3 mg/kg DMT in a fixed order across 2 test days.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Blood Pressure</measure>
    <time_frame>-60 and -30 minutes before DMT administration; 0, +5, +10, +15, +20, +30, +45, +60, and +120 minutes after DMT administration</time_frame>
    <description>Systolic and diastolic blood pressure will be measured before and several times after the administration of DMT on each test day.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Heart Rate</measure>
    <time_frame>-60 and -30 minutes before DMT administration; 0, +5, +10, +15, +20, +30, +45, +60, and +120 minutes after DMT administration</time_frame>
    <description>Heart rate will be measured before and several times after the administration of DMT on each test day.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Psychedelic Effects</measure>
    <time_frame>-60 minutes before DMT administration; 0, +30, and +60 minutes after DMT administration</time_frame>
    <description>The modified Altered States of Consciousness Rating Scale (ASC) will be used to assess drug-induced altered states of consciousness before and several times after drug administration. This is a 23-item subjective rating scale that will be completed using a visual analog scale format. Questions are scored 0 to 100 each; higher numbers indicate greater psychedelic effects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Anxiety</measure>
    <time_frame>-60 minutes before DMT administration; 0, +30, and +60 minutes after DMT administration</time_frame>
    <description>Anxiety will be assessed using a visual analog scale that subjects will be asked to score from 0 (not at all) to 100 (worst ever) to capture the net anxiety produced by DMT. This will be collected before and several times after DMT administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Reinforcing Effects</measure>
    <time_frame>+120 minutes after DMT administration</time_frame>
    <description>Subjects will be asked to answer questions such as (1) How likely are you to use this drug? and (2) How much are you willing to pay for this experience? using a visual analog scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Tolerability assessed by the VAS</measure>
    <time_frame>+120 minutes after DMT administration</time_frame>
    <description>Overall tolerability will be assessed using a visual analog scale that subjects will be asked to score from 0 (well tolerated) to 100 (intolerable) to capture the net tolerability of DMT.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Major Depressive Disorder</condition>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>0.1 mg/kg DMT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.1 mg/kg DMT administered intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.3 mg/kg DMT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.3 mg/kg DMT administered intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.1 mg/kg Dimethyltryptamine (DMT)</intervention_name>
    <description>0.1 mg/kg DMT</description>
    <arm_group_label>0.1 mg/kg DMT</arm_group_label>
    <other_name>Low Dose DMT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.3 mg/kg Dimethyltryptamine (DMT)</intervention_name>
    <description>0.3 mg/kg DMT</description>
    <arm_group_label>0.3 mg/kg DMT</arm_group_label>
    <other_name>Moderate Dose DMT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Healthy controls inclusion criteria:&#xD;
&#xD;
          -  Medically healthy&#xD;
&#xD;
          -  Psychiatrically healthy&#xD;
&#xD;
        Healthy controls exclusion criteria:&#xD;
&#xD;
          -  Unstable medical conditions&#xD;
&#xD;
          -  Psychiatric illness&#xD;
&#xD;
        Depression inclusion criteria:&#xD;
&#xD;
          -  Medically healthy&#xD;
&#xD;
          -  Diagnosis of major depressive disorder&#xD;
&#xD;
        Depression exclusion criteria:&#xD;
&#xD;
        -Unstable medical conditions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 12, 2021</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Deepak C. D'Souza</investigator_full_name>
    <investigator_title>Professor of Psychiatry</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>N,N-Dimethyltryptamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

